Here are the 10-Q quarterly reports from A SPAC III Acquisition Corp. Right (ASPCR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ASPCR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ASPCR filings page.
A SPAC III Acquisition Corp. is a blank check company seeking an ESG and materials technology Business Combination and has not begun operating activities. As of June 30, 2026, it reported total assets of $3.83 million, including $3.03 million in a Trust Account and $633,724 in cash, with working capital of $237,744.
For the six months ended June 30, 2026, the company recorded a net loss of $129,206, compared with net income in the prior year period, mainly due to substantially lower interest income on the Trust Account. Following redemptions of 5,717,419 Class A shares for $59.50 million, only 282,581 public Class A shares remain redeemable and the sponsor holds approximately 76.4% of the 2,337,581 outstanding ordinary shares.
The company has until November 12, 2026 (the extended Combination Period) to complete its initial Business Combination, or it will liquidate the Trust Account. Management states that mandatory liquidation risk and the need for additional financing raise substantial doubt about its ability to continue as a going concern. A Nasdaq notice cited stockholders’ equity below $2.5 million; Nasdaq accepted a remediation plan and granted time to regain compliance by November 12, 2026, but there is no assurance of success. A pending all-stock merger with Bioserica International Limited values the target consideration at $217.86 million, subject to customary closing conditions.
A SPAC III Acquisition Corp. reported a net loss of $113,988 for the quarter ended March 31, 2026, compared with net income of $413,202 a year earlier. The loss mainly reflects ongoing general, legal and professional expenses as interest income on the trust account declined sharply.
The Company held $670,328 of cash outside its trust and $3,006,138 of investments in its trust account, with 282,581 Class A shares classified as redeemable. After prior redemptions of 5,717,419 shares for $59,502,058, the Sponsor now owns about 76.4% of 2,337,581 outstanding shares. A pending business combination with Bioserica values that transaction at $217,860,000, and management discloses substantial doubt about the Company’s ability to continue as a going concern if no deal closes by November 12, 2026.